We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HUBS:NYSEHubSpot, Inc. Analysis

Data as of 2026-03-13 - not real-time

$260.65

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

HubSpot delivered a robust fourth‑quarter, with revenue climbing 20.4% year‑on‑year to $846.7 million and adjusted earnings per share of $3.09 beating consensus estimates, while billings—a leading indicator of future revenue—also accelerated. At $260.65 per share, the stock trades well below the DCF‑derived fair value of $418, implying roughly a 44% upside potential and a forward P/E of 17 versus a trailing P/E of 307, highlighting the market’s current pricing disconnect. Technical indicators show the price hovering just above the 20‑day SMA (259) but beneath the 50‑day (290) and 200‑day (430) averages, a bearish trend reinforced by decreasing volume and an 83% 30‑day volatility. The MACD histogram is positive, suggesting short‑term momentum, while the RSI sits at a neutral 46. Support rests around $214 and resistance near $297. Analyst sentiment is strongly positive, with 34 analysts rating the stock a “strong buy” and a median price target of $350. Despite the high trailing P/E relative to the industry, the company’s solid cash position ($1.7 billion), low debt ($262 million), and strong operating cash flow underpin its growth narrative, though elevated volatility, beta (1.33) and a bearish macro backdrop inject notable risk.
Given the blend of strong earnings momentum, attractive valuation upside from DCF, and growth‑oriented fundamentals, HubSpot presents a compelling case for investors willing to navigate its price volatility and execution risks tied to AI initiatives and market sentiment.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Positive MACD histogram indicating near‑term momentum
  • Revenue beat and strong billings suggest continued demand
  • Price near support with upside potential to $297

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF fair value implies ~44% upside
  • Forward P/E of 17 aligns with growth expectations
  • Robust cash balance and low leverage support expansion

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • AI‑driven product roadmap could drive sustainable growth
  • High volatility and beta increase market risk
  • Elevated trailing P/E and lack of dividend may limit valuation appeal

Key Metrics & Analysis

Financial Health

Revenue Growth20.40%
Profit Margin1.47%
P/E Ratio306.6
ROE2.31%
ROA0.20%
Debt/Equity12.70
P/B Ratio6.6
Op. Cash Flow$760.7M
Free Cash Flow$651.6M
Industry P/E33.6

Technical Analysis

TrendBearish
RSI46.3
Support$214.13
Resistance$297.00
MA 20$259.10
MA 50$289.99
MA 200$429.78
MACDBullish
VolumeDecreasing
Fear & Greed Index72.43

Valuation

Fair Value$418.26
Target Price$375.19
Upside/Downside43.95%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta1.33
Volatility83.08%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.